Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz
Status:
Not yet recruiting
Trial end date:
2022-06-27
Target enrollment:
Participant gender:
Summary
This will assess the effect of multiple doses of a moderate inducer of cytochrome P450 (CYP)
3A4 (efavirenz) on the pharmacokinetics (PK) of ganaplacide and lumefantrine combination.
Results from this study will provide guidance on prescribing ganaplacide and lumefantrine
combination when co-administered with moderate inducers of CYP3A4.